Related references
Note: Only part of the references are listed.Review of Enterovirus 71 Vaccines
Pele Chong et al.
CLINICAL INFECTIOUS DISEASES (2015)
Update on the development of enterovirus 71 vaccines
Yu-An Kung et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine
Shih-Min Wang et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Fold Rise in Antibody Titers by Measured by Glycoprotein-Based Enzyme-Linked Immunosorbent Assay Is an Excellent Correlate of Protection for a Herpes Zoster Vaccine, Demonstrated via the Vaccine Efficacy Curve
Peter B. Gilbert et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Hand, foot, and mouth disease in China, 2008-12: an epidemiological study
Weijia Xing et al.
LANCET INFECTIOUS DISEASES (2014)
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
Peter C. McMinn
NEW ENGLAND JOURNAL OF MEDICINE (2014)
An Inactivated Enterovirus 71 Vaccine in Healthy Children
Rongcheng Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China
Fengcai Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial
Yi-Juan Chen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Feng-Cai Zhu et al.
LANCET (2013)
Correlates of protection to influenza virus, where do we go from here?
Rebecca J. Cox
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Nomenclature for Immune Correlates of Protection After Vaccination
Stanley A. Plotkin et al.
CLINICAL INFECTIOUS DISEASES (2012)
Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines
Zhenglun Liang et al.
VACCINE (2011)
Development of enterovirus 71 vaccines
Min-Shi Lee et al.
EXPERT REVIEW OF VACCINES (2010)
Virology, epidemiology, pathogenesis, and control of enterovirus 71
Tom Solomon et al.
LANCET INFECTIOUS DISEASES (2010)
Clinical features, diagnosis, and management of enterovirus 71
Mong How Ooi et al.
LANCET NEUROLOGY (2010)
Evaluating a surrogate endpoint at three levels, with application to vaccine development
Peter B. Gilbert et al.
STATISTICS IN MEDICINE (2008)
Prediction of pertussis vaccine efficacy using a correlates of protection model
Robert C. Kohberger et al.
VACCINE (2008)
A framework for assessing immunological correlates of protection in vaccine trials
Li Qin et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide
Damian Guang Wei Foo et al.
MICROBES AND INFECTION (2007)
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
George R. Siber et al.
VACCINE (2007)
A model for immunological correlates of protection
AJ Dunning
STATISTICS IN MEDICINE (2006)
Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan
LY Chang et al.
PEDIATRICS (2002)
Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
CN Wu et al.
VACCINE (2001)
Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia
P McMinn et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
